Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Disease analysis

Disease analysis


loader
  • Sort by Average rating
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Triple-Negative Breast Cancer KOL Interview – UK

    $599.00

    A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

    October 31, 2019
    Find out more

  • Market Spotlight: Atrial Fibrillation

    $1,318.00

    This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

    April 7, 2022
    Find out more

  • 2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

    $4,750.00

    The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for…

    October 18, 2019
    Find out more

  • Minimally Invasive Heart Valve Repair and Replacement Devices

    $4,750.00

    This comprehensive medical market and technology report provides an overview and in-depth market analysis of the transcatheter heart valve products used in the treatment of heart valve stenosis, regurgitation, and other valvular disorders.

    October 13, 2019
    Find out more

  • Drug Delivery: Inhalation Devices

    $4,750.00

    This comprehensive market and medical technology report provides an overview of the inhalation-based devices used in the management of asthma and chronic obstructive pulmonary disease (COPD), and includes an in-depth, product-specific market analysis. Countries covered by this report comprise the US, the five major EU markets (France, Germany, Italy, Spain, and the UK), and Japan.

    October 7, 2019
    Find out more

  • Diabetes Management: Insulin Pumps Market (2019)

    $4,750.00

    This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.

    September 30, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – New Jersey, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Rheumatoid Arthritis Payer Interview – Pennsylvania, US

    $599.00

    A US payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

    August 22, 2019
    Find out more

  • Rheumatoid Arthritis Payer Interview – UK

    $599.00

    A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

    August 22, 2019
    Find out more

  • Market Spotlight: Hereditary Angioedema

    $1,318.00

    This Market Spotlight report covers the Hereditary Angioedema market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    April 7, 2022
    Find out more

  • Rheumatoid Arthritis KOL Interview – New Jersey, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

    $1,318.00

    This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    April 13, 2022
    Find out more

  • Rheumatoid Arthritis KOL Interview – California, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – UK

    $599.00

    A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Market Spotlight: Systemic Lupus Erythematosus (SLE)

    $1,318.00

    This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    May 23, 2022
    Find out more
Page 3 of 12
Page 3 of 12‹12345›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top